NDA 020908 · Novo Nordisk INC
Vagifem
Estradiol · Vaginal · Estrogen
Last checked: Nov 20, 2026Latest source record: Feb 15, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1999
Mar 26, 1999
Approved uses
2
Original approval plus efficacy supplements
Registered trials
1,701
351 Phase 3, 176 recruiting
FAERS reports
51,288
25,836 serious, 1,050 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, PROBABLE DEMENTIA, and BREAST CANCER Estrogen-Alone Therapy Endometrial Cancer There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Adding a progestogen to estrogen therapy has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer. Perform adequate diagnostic measures, including directed or random endometrial sampling when indicated, to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding [see Warnings and Precautions ( 5.3 )]. Cardiovascular Disorders and Probable Dementia The Women’s Health Initiative (WHI) estrogen-alone substudy reported increased risks of stroke and deep vein thrombosis (DVT) in postmenopausal women (50 to 79 years of age) during 7.1 years of treatment...
What it is approved for
From the label in effect Feb 10, 2025.
• Vagifem is an estrogen indicated for the treatment of atrophic vaginitis due to menopause ( 1.1 ). 1.1 Treatment of Atrophic Vaginitis due to Menopause
Mechanism: Endogenous estrogens are largely responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal intracellular human estrogen and is substantially more potent than its metabolites, estrone and estriol, at the receptor level. The primary source of estrogen in normally cycling adult women is the ovarian follicle, which secretes 70 to 500 mcg of estradiol daily, depending on the phase of the menstrual cycle. After...
Therapeutic areas: Endocrinology and women's health
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 25, 2009 Supplement 13 · Efficacy ReviewLabel
- Mar 26, 1999 Original approval · Type 3 - New Dosage Form LabelReviewLetter
2 products under this application
- VAGIFEM · ESTRADIOL 25MCG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, VAGINAL · Discontinued
- VAGIFEM · ESTRADIOL 10MCG · TABLET, VAGINAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Estradiol" as an intervention, any sponsor and status, largest first.
- Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug EfficacyPivotal-lookingActive, not recruiting
Medical Research CouncilGovernment (non-federal)
NCT00268476 · 11,992 participants · Start Jul 8, 2005 · Primary completion Mar 2026
Drug: Celecoxib; Docetaxel and 7 more · For: Prostate Cancer
Sites: Lausanne, Switzerland; Winterthur, Switzerland; Chur, Switzerland · 120 sites in all
- Short-term Effects of Transdermal Estradiol on Female COVID-19 PatientsPivotal-lookingCompleted
Istanbul University - CerrahpasaAcademic, hospital or other
NCT05774405 · 9,169 participants · Start Jul 1, 2020 · Primary completion Jul 31, 2021
Drug: Climara 0.1Mg/24Hr Transdermal System · For: COVID-19; Hormone Replacement Therapy
Sites: Istanbul, Turkey (Türkiye)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NIH
NCT00006324 · 6,360 participants · Start Dec 1999
Drug: Ethinyl estradiol/levonorgestrel; Medroxyprogesterone acetate · For: HIV Infections
Sites: Research Triangle Park, North Carolina
- A Study to Evaluate the Efficacy and Safety of DR-103 for the Prevention of PregnancyPivotal-lookingCompleted
Teva Women's HealthTeva (TEVA)
NCT00996580 · 3,597 participants · Start Oct 2009 · Primary completion Sep 2011
Drug: DR-103 · For: Pregnancy Prevention
Sites: Montgomery, Alabama; Phoenix, Arizona; Tucson, Arizona · 94 sites in all
- Study of the Contraceptive Efficacy and Safety of a NOMAC-E2 Combined Oral Contraceptive (COC)(P06448)Pivotal-lookingTerminated
Organon and CoIndustry
NCT01656434 · 3,173 participants · Start Nov 2, 2012 · Primary completion Feb 12, 2014
Drug: NOMAC-E2; NETA-EE and 2 more · For: Contraception
- Contraceptive Efficacy and Safety of NOMAC-E2 Combined Oral ContraceptivePivotal-lookingTerminated
Organon and CoIndustry
NCT05264506 · 3,055 participants · Start Feb 17, 2022 · Primary completion Jan 12, 2024
Drug: NOMAC-E2 COC · For: Contraception
Sites: Birmingham, Alabama; Dothan, Alabama; Mobile, Alabama · 103 sites in all
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialPivotal-lookingRecruiting
National Cancer Institute (NCI)NIH
NCT05564377 · 2,900 participants (planned) · Start Apr 7, 2023 · Primary completion Jul 1, 2030
Drug: Alpelisib; Binimetinib and 13 more · For: Advanced Malignant Solid Neoplasm; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8 and 12 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 484 sites in all
- A Study to Evaluate the Efficacy and Safety of DR-102 for the Prevention of PregnancyPivotal-lookingCompleted
Teva Branded Pharmaceutical Products R&D, Inc.Teva (TEVA)
NCT01178125 · 2,858 participants · Start Aug 2010 · Primary completion Jan 2013
Drug: DR-102 · For: Contraception; Female Contraception
Sites: Montgomery, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 62 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective4,227
- headache3,188
- fatigue3,185
- nausea3,175
- off label use2,652
- pain2,331
- diarrhoea2,200
- dizziness1,956
- arthralgia1,954
- breast cancer female1,721
- dyspnoea1,714
- pruritus1,707
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 562 |
| 2005 | 617 |
| 2006 | 459 |
| 2007 | 1,513 |
| 2008 | 501 |
| 2009 | 689 |
| 2010 | 1,089 |
| 2011 | 947 |
| 2012 | 1,316 |
| 2013 | 1,057 |
| 2014 | 1,323 |
| 2015 | 2,222 |
| 2016 | 2,721 |
| 2017 | 2,436 |
| 2018 | 2,790 |
| 2019 | 3,242 |
| 2020 | 3,207 |
| 2021 | 3,051 |
| 2022 | 3,260 |
| 2023 | 3,760 |
| 2024 | 3,898 |
| 2025 | 5,447 |
| 2026 | 5,180 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Vagifem (Estradiol)
2024 spending
$3.1M
Beneficiaries
2,322
7,733 claims
Per beneficiary
$1,323
$19.97 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $4,945,697 |
| 2021 | $4,088,997 |
| 2022 | $3,662,059 |
| 2023 | $3,277,770 |
| 2024 | $3,072,848 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Effect of Soy Isoflavones on Measures of Estrogenicity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Viscardi G, Back S, Ahmed A, et al. · Adv Nutr 2025 · Systematic Review, Meta-Analysis
- Systematic Review and Meta-analysis: Changes of Gut Microbiota before and after Menopause.
Yang M, Wen S, Zhang J, et al. · Dis Markers 2022 · Meta-Analysis, Systematic Review
- Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol.
Hodis HN, Mack WJ, Henderson VW, et al. · N Engl J Med 2016 · Comparative Study, Randomized Controlled Trial
- The Effect of Sex Hormones on Joint Ligament Properties: A Systematic Review and Meta-analysis.
Gilmer G, Crasta N, Tanaka MJ · Am J Sports Med 2025 · Systematic Review, Meta-Analysis
- A systematic review and meta-analysis of venous thrombosis risk among users of combined oral contraception.
Dragoman MV, Tepper NK, Fu R, et al. · Int J Gynaecol Obstet 2018 · Meta-Analysis, Systematic Review
- Pharmacological Treatments for Menopausal Vasomotor Symptoms: A Systematic Review and Bayesian Network Meta-Analysis of Efficacy and Safety.
Oliveira Amador WF, Saraiva CA, Ruelas MG, et al. · Eur J Obstet Gynecol Reprod Biol 2025 · Network Meta-Analysis, Systematic Review
Sponsor: Novo Nordisk
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.